16 reports

Filgrastim acts to raise the phagocytic activity of mature neutrophils.

  • Antimalarials
  • United States
  • World
  • Product Initiative
  • Coherus BioSciences, Inc.

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Pharmaceutical
  • World
  • Product Initiative
  • Santen Pharmaceutical Co., Ltd.

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Ophthalmology
  • United States
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Therapy
  • United States
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Infectious Disease
  • Pharmaceutical
  • Vaccine
  • World

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Pharmaceutical
  • World
  • Product Initiative
  • Santen Pharmaceutical Co., Ltd.

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Cholesterol
  • South Korea
  • United States
  • World
  • Official Title

filgrastim; melphalan Boston Medical Center National Institutes of Health ## Nov 2000 ## Jun 2005 ## ## ## ## ## DNA Synthesis Inhibitor DNA A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan and Dexamethasone (V-MD) in Patients with Symptomatic AL-Amyloidosis or Light Chain Depo

  • Antimalarials
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • In Vitro Diagnostics
  • Molecular Diagnostic
  • Pharmaceutical
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

filgrastim Medical University of Bialystok ## Mar 2013 ## Jun 2016 ## ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborator(s) Estimated Star

  • Antimalarials
  • Therapy
  • World
  • Product Initiative
  • Sarepta Therapeutics, Inc.
  • Antimalarials
  • United States
  • World
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Therapy
  • United States
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Antimalarials
  • Leukemia
  • United States
  • Product Initiative
  • Sareum Holdings plc

IN DECEMBER 2014, THE COMPANY RECEIVED FDA APPROVAL TO GRANIX (TBO-FILGRASTIM) INJECTION FOR SELF-ADMINISTRATION.

  • Antimalarials
  • United States
  • Merck & Co., Inc.
  • Mylan Inc.
  • Pfizer Inc.